SPECIFICITY FOR IN-VIVO GRAFT PROLONGATION IN GAMMA-DELTA T-CELL RECEPTOR(-VEIN DONOR-SPECIFIC PREIMMUNIZATION AND SKIN ALLOGRAFTS() HYBRIDOMAS DERIVED FROM MICE GIVEN PORTAL)
Rm. Gorczynski et al., SPECIFICITY FOR IN-VIVO GRAFT PROLONGATION IN GAMMA-DELTA T-CELL RECEPTOR(-VEIN DONOR-SPECIFIC PREIMMUNIZATION AND SKIN ALLOGRAFTS() HYBRIDOMAS DERIVED FROM MICE GIVEN PORTAL), The Journal of immunology, 159(8), 1997, pp. 3698-3706
gamma delta TCR+ hybridoma cells prepared from mesenteric lymph node c
ells of animals receiving donor-specific immunization via the portal v
ein can adoptively transfer this increased graft survival to naive ani
mals. Analysis of TCR gamma-chain junctional sequence diversity sugges
ted that some 40 to 50% of the hybridomas expressed gamma-chain juncti
onal sequence diversity and were stimulated to produce cytokines both
by heat shock proteins and by minor histocompatibility Ag-specific irr
adiated peritoneal cells. The remaining gamma delta TCR+ hybridoma cel
ls expressed TCR with a common gamma-chain junctional sequence and wer
e stimulated to cytokine production by MHC-matched, but minor histocom
patibility Ag-mismatched (as well as matched), peritoneal cells, but n
ot by heat shock proteins. We have compared the effectiveness of repre
sentative hybridomas expressing unique gamma-chain junctional sequence
s or common gamma-chain junctional sequences for prolongation of donor
-specific or third-party (MHC-matched or MHC-mismatched) skin grafts.
Our data show a good correlation between the specificity for stimulati
on for cytokine production in vitro and efficacy in graft prolongation
assays in vivo. Hybridoma cells expressing unique gamma-chain junctio
nal sequences that showed Ag-specific stimulation of cytokine producti
on in vitro and skin graft survival in vivo augmented survival of thir
d-party skin grafts if simultaneously transplanted with both Ag-specif
ic and third-party skin grafts. Graft prolongation in vivo using cells
from either population of gamma delta TCR+ hybridomas was decreased b
y infusion of anti-IL-10 mAb and abolished when both anti-IL-10 and an
ti-TGF-beta Abs were used together.